Boost For India’s Generic Pharma Majors
Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a growing market.
viatris
October 2024
November 2022
February 2022
Biocon Biologics completes acquisition of Viatris biosimilars biz for $3.3 bn
Biocon Biologics, Viatris get all key approvals from global regulators, including US FTC, CCI, RBI, and investors. Biocon Ltd’s stake in Biocon Biologics to rise to 68%.
Bold bet! Biocon Biologics buys Viatris biosimilars assets for $3.33 billion
Viatris will receive $2 billion in cash and up to $335 million as additional payments expected to be paid in 2024.
